Wisconsin Collaborative for Quality Healthcare

View Our Reports

print this page

Ischemic Vascular Disease: Daily Aspirin or Other Antiplatelet Therapy Unless Contraindicated This is a measure developed by the Wisconsin Collaborative for Healthcare Quality (WCHQ).

Your Search Results: 11 Clinics in the Mayo Clinic Health System health system


The results below represent the care of 1,799 patients with coronary and other atherosclerotic vascular disease. Read More About This Measure

Reporting Period:

Sort By Rank | Sort By Name  
Btn Export
CLINIC_NAME

The number of patients or providers is too small for
purposes of reliably reporting performance
Mayo Clinic Health System - Franciscan Healthcare in Arcadia

The number of patients or providers is too small for
purposes of reliably reporting performance
Mayo Clinic Health System - Franciscan Healthcare in Caledonia

The number of patients or providers is too small for
purposes of reliably reporting performance
Mayo Clinic Health System - Franciscan Healthcare in Holmen
N=169
96.45 %
View Historical Data
Mayo Clinic Health System - Franciscan Healthcare in La Crescent

The number of patients or providers is too small for
purposes of reliably reporting performance
Mayo Clinic Health System - Franciscan Healthcare in La Crosse
N=677
96.75 %
View Historical Data
Mayo Clinic Health System - Franciscan Healthcare in Onalaska
N=415
95.66 %
View Historical Data
Mayo Clinic Health System - Franciscan Healthcare in Prairie du Chien
N=140
98.57 %
View Historical Data
Mayo Clinic Health System - Franciscan Healthcare in Sparta
N=169
97.63 %
View Historical Data
Mayo Clinic Health System - Franciscan Healthcare in Tomah
N=229
95.63 %
View Historical Data
Mayo Clinic Health System - Franciscan Healthcare in Waukon

The number of patients or providers is too small for
purposes of reliably reporting performance

There has been important evidence from clinical trials that further supports and broadens the merits of risk-reduction therapies for patients with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease.

Based on trials involving other secondary prevention therapies, the ACC and AHA recommends aspirin in all patients, unless contraindicated, with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease. The ACC and AHA also recommend the use of other antiplatelet agents based on disease type and clinical conditions.

This measure shows the percentage of people 18 to 75 years of age with a diagnosis coronary or other atherosclerotic vascular disease who were prescribed oral antiplatelet therapy, unless contraindicated, in the measurement year.


Disclaimer: Measures reported by WCHQ healthcare organizations represent a specific aspect of care in relation to an evidence-based standard, but are not clinical guidelines and do not establish standards of care.